Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study
Philippe Ruszniewski, Juan W. Valle, Catherine Lombard‐Bohas, et al.
Digestive and Liver Disease (2016) Vol. 48, Iss. 5, pp. 552-558
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Somatostatin Analogs in Clinical Practice: A Review
Mariana Gomes-Porras, Jersy Cárdenas‐Salas, Cristina Álvarez‐Escolá
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 5, pp. 1682-1682
Open Access | Times Cited: 196
Carcinoid-syndrome: recent advances, current status and controversies
Tetsuhide Ito, Lingaku Lee, Robert T. Jensen
Current Opinion in Endocrinology Diabetes and Obesity (2017) Vol. 25, Iss. 1, pp. 22-35
Open Access | Times Cited: 118
Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (Elect): A Randomized, Double-Blind, Placebo-Controlled Trial
Aaron I. Vinik, Edward M. Wolin, Nilani Liyanage, et al.
Endocrine Practice (2016) Vol. 22, Iss. 9, pp. 1068-1080
Closed Access | Times Cited: 89
Management of carcinoid syndrome: a systematic review and meta-analysis
Johannes Hofland, Aura D. Herrera‐Martínez, Wouter T. Zandee, et al.
Endocrine Related Cancer (2019) Vol. 26, Iss. 3, pp. R145-R156
Open Access | Times Cited: 77
Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies
Tetsuhide Ito, Lingaku Lee, Robert T. Jensen
Expert Opinion on Pharmacotherapy (2016) Vol. 17, Iss. 16, pp. 2191-2205
Open Access | Times Cited: 86
Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
Maria J. Klomp, Simone U. Dalm, Marion de Jong, et al.
Reviews in Endocrine and Metabolic Disorders (2020) Vol. 22, Iss. 3, pp. 495-510
Open Access | Times Cited: 53
Management of Diarrhea in Patients With Carcinoid Syndrome
Boris G. Naraev, Magnus Halland, Daniel M. Halperin, et al.
Pancreas (2019) Vol. 48, Iss. 8, pp. 961-972
Open Access | Times Cited: 37
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms
Federico Gatto, Federica Barbieri, Marica Arvigo, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 16, pp. 3940-3940
Open Access | Times Cited: 36
Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours
Caroline Martini, Eva‐Maria Gamper, Lisa M. Wintner, et al.
Health and Quality of Life Outcomes (2016) Vol. 14, Iss. 1
Open Access | Times Cited: 38
Telotristat ethyl: a new option for the management of carcinoid syndrome
Ángela Lamarca, Jorge Barriuso, Mairéad G. McNamara, et al.
Expert Opinion on Pharmacotherapy (2016) Vol. 17, Iss. 18, pp. 2487-2498
Open Access | Times Cited: 32
Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR
David Cella, Jennifer L. Beaumont, Stacie Hudgens, et al.
Clinical Therapeutics (2018) Vol. 40, Iss. 12, pp. 2006-2020.e2
Open Access | Times Cited: 31
From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 3
Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
Edward M. Wolin, Amandine Manon, Christophe Chassaing, et al.
Journal of Gastrointestinal Cancer (2016) Vol. 47, Iss. 4, pp. 366-374
Open Access | Times Cited: 26
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study
George A. Fisher, Edward M. Wolin, Nilani Liyanage, et al.
The Oncologist (2017) Vol. 23, Iss. 1, pp. 16-24
Open Access | Times Cited: 26
Sex differences in carcinoid syndrome: A gap to be closed
Rosaria Maddalena Ruggeri, Barbara Altieri, Erika Grossrubatcher, et al.
Reviews in Endocrine and Metabolic Disorders (2022) Vol. 23, Iss. 3, pp. 659-669
Closed Access | Times Cited: 13
The safety of lanreotide for neuroendocrine tumor
Amandeep Godara, Nauman Siddiqui, Margaret M. Byrne, et al.
Expert Opinion on Drug Safety (2018) Vol. 18, Iss. 1, pp. 1-10
Closed Access | Times Cited: 21
Living With Neuroendocrine Tumors: Assessment of Quality of Life Through a Mobile Application
Jared Adams, David Ray, R. Willmon, et al.
JCO Clinical Cancer Informatics (2019), Iss. 3, pp. 1-10
Open Access | Times Cited: 20
Recent Advances in the Management of Typical and Atypical Lung Carcinoids
Natalie Prinzi, Roberta Rossi, Claudia Proto, et al.
Clinical Lung Cancer (2020) Vol. 22, Iss. 3, pp. 161-169
Closed Access | Times Cited: 19
Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review
Rohit Gosain, Medhavi Gupta, Arya Mariam Roy, et al.
Cancers (2022) Vol. 14, Iss. 6, pp. 1428-1428
Open Access | Times Cited: 12
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?
Maria Passhak, Mairéad G. McNamara, Richard Hubner, et al.
Best Practice & Research Clinical Endocrinology & Metabolism (2023) Vol. 37, Iss. 5, pp. 101836-101836
Closed Access | Times Cited: 7
An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors
Aayushi Sood, Malak Munir, Omar Syed, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 8, pp. 949-957
Closed Access | Times Cited: 2
Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review
Gurleen Pasricha, Parikshit Padhi, Nour Daboul, et al.
Clinical Therapeutics (2017) Vol. 39, Iss. 11, pp. 2146-2157
Open Access | Times Cited: 21
Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise
Mirco Bartolomei, Alfredo Berruti, Massimo Falconi, et al.
Cancers (2022) Vol. 14, Iss. 10, pp. 2501-2501
Open Access | Times Cited: 11
Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review
Mohid S. Khan, Thomas Walter, Amy Buchanan-Hughes, et al.
World Journal of Gastroenterology (2020) Vol. 26, Iss. 30, pp. 4537-4556
Open Access | Times Cited: 13
Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome
Anna Koumarianou, Kosmas Daskalakis, Marina Tsoli, et al.
Journal of Neuroendocrinology (2022) Vol. 34, Iss. 7
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top